At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 737 enrolled
Drug / intervention
Dulaglutide +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating Dulaglutide, Glimepiride, and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 737 participants across 30 sites in 3 countries.
Detailed Summary
The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to glimepiride in participants with type 2 diabetes mellitus who have inadequate glycemic control with oral antihyperglycemic medication (OAM) or are OAM-naïve.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesChina, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedJul 2012
Primary CompletionAug 2014
TodayJul 2026
First PostedJul 19, 2012
Enrollment StartJul 1, 2012
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.0 years ago
Interventions
Dulaglutidedrug
Administered SC
Glimepiridedrug
Administered orally
Placebo as Capsulesdrug
Placebo for glimepiride is administered orally as one to three capsules daily.
Placebo as SC Injectiondrug
Placebo for dulaglutide is administered as one SC injection.